Fig. 2: Patients with post-RS recommendations for chemo-endocriine therapy (CT + HT): actual number based on previous RS cut points and expected percentage assuming decision-making according to TAILORx results (N = 1683). | npj Breast Cancer

Fig. 2: Patients with post-RS recommendations for chemo-endocriine therapy (CT + HT): actual number based on previous RS cut points and expected percentage assuming decision-making according to TAILORx results (N = 1683).

From: PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Fig. 2

Pre RS: treatment recommendations before avalability of the Recurrence Score result. Post RS: treatment recommendations accounting for the Recurrence Score result.

Back to article page